Skip to main content
. 2023 Apr 1;15(4):e37002. doi: 10.7759/cureus.37002

Table 3. Susceptibility profile of CZA compared to other BL-BLIs among MDR Enterobacterales and Pseudomonas aeruginosa.

CZA, ceftazidime-avibactam; AMC, amoxicillin-clavulanate; PTZ, piperacillin-tazobactam; CFS, cefoperazone-sulbactam; BL-BLIs, β-lactam-β-lactamase inhibitors; MDR: multidrug-resistant.

CZA AMC susceptibility PTZ susceptibility CFS susceptibility
CZA (S) (30.6%) 2.9 %   6.2%   8.6%  
CZA (R) (69.4%) 1.1%   0.6%   0.6%